FOCUS ON BIOTECHNOLOGICAL INNOVATIONS FOR THE BENEFIT OF PATIENTS
The expertise of ten23 health is in demand in many areas, because, as Mahler points out, no two collaborations are alike. “We develop, 100
|
Issue 11 1
|
November 2023
In the area of drug development of a new sterile medicinal product, the company advises on a suitable development and commercialisation strategy and assists in the selection of the formulation (composition), the dosage form of a drug, the development of a suitable manufacturing process, the selection of the primary packaging materials (vial, syringe or cartridge), and the integration of application aids in different clinical development and use phases (e.g., auto-injectors, pens or infusers). “When this is done, we can also produce and analytically test the sterile products for our clients,” says Mahler, “and thus transform a pharmaceutical ingredient into a suitable sterile drug and guarantee quality and safety for the patients.”
“Our organisational structure is holocratic and based on the principle of role-andstrength-based work and the so-called Loop Approach. This means that we do not rely on traditional reporting structures, bureaucracy, or classic control mechanisms, but trust our employees, their expertise, autonomy and motivation.” www.ten23.health
PHOTOS: TEN23 HEALTH AG
produce and test sterile drugs for different molecules, areas of application and development phases. Our service portfolio adapts to the respective project and client needs and therefore covers different areas.”
I
Since it was founded in 2021, the Swiss company ten23 health has become a popular partner for both large pharmaceutical companies and start-ups in the biotech sector. “We are a highly specialised contract company in the field of sterile drugs, i.e. drugs for infusion or injection. More precisely, our clients commission us with the development, production and testing of sterile drugs containing biotechnological active ingredients such as bispecific antibodies or RNA, but also synthetically produced molecules. We provide solutions to our clients’ challenges, for example in the development of highly concentrated and viscous protein formulations or in high-precision fillings in ready-to-use syringes and cartridges,” explains Hanns-Christian Mahler, CEO and Chairman of the Board of the innovative company.
The duration of each collaboration varies and ranges from a few months to several years or even the entire life cycle of a drug. The final structure of the collaboration is always defined by the client, who can always rely on ten23 health to deliver world-renowned Swiss quality, precision and expertise.
TEXT: SILKE HENKELE
Start-ups and research departments of large pharmaceutical companies are often the driving forces behind innovative ideas in the pharmaceutical sector. Courageous visionaries and entrepreneurs use their energy and passion to change the world. But the road to implementation is often rocky.